Literature DB >> 24696087

Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance.

Raimund M Vielnascher1, Eva Hainzl, Nicole R Leitner, Michael Rammerstorfer, David Popp, Agnieszka Witalisz, Rita Rom, Marina Karaghiosoff, Thomas Kolbe, Simone Müller, Thomas Rülicke, Caroline Lassnig, Birgit Strobl, Mathias Müller.   

Abstract

Tyrosine kinase 2 (TYK2) has a pivotal role in immunity to infection and tumor surveillance. It is associated with several cytokine receptor chains including type I interferon (IFN) receptor 1 (IFNAR1), interleukin- (IL-) 12 receptor beta 1 (IL-12Rb1) and IL-10R2. We have generated a mouse with a conditional Tyk2 null allele and proved integrity of the conditional Tyk2 locus. TYK2 was successfully removed by the use of ubiquitous and tissue-specific Cre-expressing mouse strains. Myeloid TYK2 was found to critically contribute to the defense against murine cytomegalovirus. Ubiquitous TYK2 ablation severely impaired tumor immunosurveillance, while deletion in myeloid, dendritic or T cells alone showed no effect. The conditional Tyk2 mouse strain will be instrumental to further dissect TYK2 functions in infection, inflammation and cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24696087     DOI: 10.1007/s11248-014-9795-y

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  46 in total

1.  Novel functions of tyrosine kinase 2 in the antiviral defense against murine cytomegalovirus.

Authors:  Birgit Strobl; Ivan Bubic; Ute Bruns; Ralf Steinborn; Robert Lajko; Thomas Kolbe; Marina Karaghiosoff; Ulrich Kalinke; Stipan Jonjic; Mathias Müller
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

2.  Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.

Authors:  Rupal Ramakrishnan; Deepak Assudani; Srinivas Nagaraj; Terri Hunter; Hyun-Il Cho; Scott Antonia; Soner Altiok; Esteban Celis; Dmitry I Gabrilovich
Journal:  J Clin Invest       Date:  2010-03-15       Impact factor: 14.808

3.  Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant.

Authors:  M Hilburger Ryan; S I Abrams
Journal:  Cancer Immunol Immunother       Date:  2001-01       Impact factor: 6.968

4.  All is fair in virus-host interactions: NK cells and cytomegalovirus.

Authors:  Marina Babić; Astrid Krmpotić; Stipan Jonjić
Journal:  Trends Mol Med       Date:  2011-08-17       Impact factor: 11.951

5.  Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity.

Authors:  Yoshiyuki Minegishi; Masako Saito; Tomohiro Morio; Ken Watanabe; Kazunaga Agematsu; Shigeru Tsuchiya; Hidetoshi Takada; Toshiro Hara; Nobuaki Kawamura; Tadashi Ariga; Hideo Kaneko; Naomi Kondo; Ikuya Tsuge; Akihiro Yachie; Yukio Sakiyama; Tsutomu Iwata; Fumio Bessho; Tsutomu Ohishi; Kosuke Joh; Kohsuke Imai; Kazuhiro Kogawa; Miwa Shinohara; Mikiya Fujieda; Hiroshi Wakiguchi; Srdjan Pasic; Mario Abinun; Hans D Ochs; Eleonore D Renner; Annette Jansson; Bernd H Belohradsky; Ayse Metin; Norio Shimizu; Shuki Mizutani; Toshio Miyawaki; Shigeaki Nonoyama; Hajime Karasuyama
Journal:  Immunity       Date:  2006-11       Impact factor: 31.745

6.  TYK2 is a key regulator of the surveillance of B lymphoid tumors.

Authors:  Dagmar Stoiber; Boris Kovacic; Christian Schuster; Carola Schellack; Marina Karaghiosoff; Rita Kreibich; Eva Weisz; Michaela Artwohl; Olaf C Kleine; Mathias Muller; Sabina Baumgartner-Parzer; Jacques Ghysdael; Michael Freissmuth; Veronika Sexl
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

7.  TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.

Authors:  Takaomi Sanda; Jeffrey W Tyner; Alejandro Gutierrez; Vu N Ngo; Jason Glover; Bill H Chang; Arla Yost; Wenxue Ma; Angela G Fleischman; Wenjun Zhou; Yandan Yang; Maria Kleppe; Yebin Ahn; Jessica Tatarek; Michelle A Kelliher; Donna S Neuberg; Ross L Levine; Richard Moriggl; Mathias Müller; Nathanael S Gray; Catriona H M Jamieson; Andrew P Weng; Louis M Staudt; Brian J Druker; A Thomas Look
Journal:  Cancer Discov       Date:  2013-03-07       Impact factor: 39.397

8.  Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection.

Authors:  Luisa Cervantes-Barragán; Ulrich Kalinke; Roland Züst; Martin König; Boris Reizis; Constantino López-Macías; Volker Thiel; Burkhard Ludewig
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

9.  Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance.

Authors:  Hisataka Kobayashi; Sigrid Dubois; Noriko Sato; Helen Sabzevari; Yoshio Sakai; Thomas A Waldmann; Yutaka Tagaya
Journal:  Blood       Date:  2004-09-14       Impact factor: 22.113

10.  Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy.

Authors:  Jan P Tuckermann; Anna Kleiman; Richard Moriggl; Rainer Spanbroek; Anita Neumann; Anett Illing; Björn E Clausen; Brenda Stride; Irmgard Förster; Andreas J R Habenicht; Holger M Reichardt; François Tronche; Wolfgang Schmid; Günther Schütz
Journal:  J Clin Invest       Date:  2007-04-19       Impact factor: 14.808

View more
  11 in total

1.  NK Cells Require Cell-Extrinsic and -Intrinsic TYK2 for Full Functionality in Tumor Surveillance and Antibacterial Immunity.

Authors:  Natalija Simonović; Agnieszka Witalisz-Siepracka; Katrin Meissl; Caroline Lassnig; Ursula Reichart; Thomas Kolbe; Matthias Farlik; Christoph Bock; Veronika Sexl; Mathias Müller; Birgit Strobl
Journal:  J Immunol       Date:  2019-02-04       Impact factor: 5.422

2.  Intestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis.

Authors:  Eva Hainzl; Silvia Stockinger; Isabella Rauch; Susanne Heider; David Berry; Caroline Lassnig; Clarissa Schwab; Felix Rosebrock; Gabriel Milinovich; Michaela Schlederer; Michael Wagner; Christa Schleper; Alexander Loy; Tim Urich; Lukas Kenner; Xiaonan Han; Thomas Decker; Birgit Strobl; Mathias Müller
Journal:  J Immunol       Date:  2015-10-02       Impact factor: 5.422

3.  Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine.

Authors:  Madeline E Kavanagh; Benjamin D Horning; Roli Khattri; Nilotpal Roy; Justine P Lu; Landon R Whitby; Elva Ye; Jaclyn C Brannon; Albert Parker; Joel M Chick; Christie L Eissler; Ashley J Wong; Joe L Rodriguez; Socorro Rodiles; Kim Masuda; John R Teijaro; Gabriel M Simon; Matthew P Patricelli; Benjamin F Cravatt
Journal:  Nat Chem Biol       Date:  2022-09-12       Impact factor: 16.174

Review 4.  The molecular regulation of Janus kinase (JAK) activation.

Authors:  Jeffrey J Babon; Isabelle S Lucet; James M Murphy; Nicos A Nicola; Leila N Varghese
Journal:  Biochem J       Date:  2014-08-15       Impact factor: 3.857

5.  TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death.

Authors:  Wenjing Qin; Abigail Godec; Xiaochun Zhang; Cuige Zhu; Jieya Shao; Yu Tao; Xianzhang Bu; Angela C Hirbe
Journal:  Cancer Med       Date:  2019-07-06       Impact factor: 4.452

6.  Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.

Authors:  Lukas Kenner; Olaf Merkel; Nicole Prutsch; Elisabeth Gurnhofer; Tobias Suske; Huan Chang Liang; Michaela Schlederer; Simone Roos; Lawren C Wu; Ingrid Simonitsch-Klupp; Andrea Alvarez-Hernandez; Christoph Kornauth; Dario A Leone; Jasmin Svinka; Robert Eferl; Tanja Limberger; Astrid Aufinger; Nitesh Shirsath; Peter Wolf; Thomas Hielscher; Christina Sternberg; Fritz Aberger; Johannes Schmoellerl; Dagmar Stoiber; Birgit Strobl; Ulrich Jäger; Philipp B Staber; Florian Grebien; Richard Moriggl; Mathias Müller; Giorgio G Inghirami; Takaomi Sanda; A Thomas Look; Suzanne D Turner
Journal:  Leukemia       Date:  2018-08-21       Impact factor: 11.528

7.  Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer.

Authors:  Jin-Chul Kim; You-Jeong Heo; So-Young Kang; Jeeyun Lee; Kyoung-Mee Kim
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

8.  T Cell-Intrinsic CDK6 Is Dispensable for Anti-Viral and Anti-Tumor Responses In Vivo.

Authors:  Klara Klein; Agnieszka Witalisz-Siepracka; Dagmar Gotthardt; Benedikt Agerer; Felix Locker; Reinhard Grausenburger; Vanessa Maria Knab; Andreas Bergthaler; Veronika Sexl
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

9.  TYK2 licenses non-canonical inflammasome activation during endotoxemia.

Authors:  Andrea Poelzl; Caroline Lassnig; Simone Tangermann; Dominika Hromadová; Ursula Reichart; Riem Gawish; Kristina Mueller; Richard Moriggl; Andreas Linkermann; Martin Glösmann; Lukas Kenner; Mathias Mueller; Birgit Strobl
Journal:  Cell Death Differ       Date:  2020-09-14       Impact factor: 12.067

10.  In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity.

Authors:  Michaela Prchal-Murphy; Agnieszka Witalisz-Siepracka; Karoline T Bednarik; Eva Maria Putz; Dagmar Gotthardt; Katrin Meissl; Veronika Sexl; Mathias Müller; Birgit Strobl
Journal:  Oncoimmunology       Date:  2015-05-26       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.